Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.
Also called NCT03860935
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 632 participants
- Registry
-
NCT03860935 -
2018-004280-32
-
- Other papers using this trial's data
- Comparison of in-clinic assessment of 6MWT by conventional method and using wearable sensors for patients with ATTR-CM
- Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy
- Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy
- Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial
- Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
- Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
- Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Greece, Ireland, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03860935. Randomized; quadruple masking; primary purpose treatment. Start 2019-03-19 (actual); primary completion 2023-05-11 (actual). Results posted on 2024-06-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
- Acronym
- ATTRibute-CM
- Condition
- Amyloidosis
- Condition
- Amyloid Cardiomyopathy
- Condition
- Transthyretin Amyloidosis
- Condition
- Cardiomyopathies
- Condition
- Heart Diseases
- Intervention (Drug)
- acoramidis
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
Record details
- Record id
cardio:ct-nct03860935- Content hash
4a099f745615b2c928303258f31c28da7aefcafa40aac69c0deb88ad34516fb4